News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dr. Andrew Zhu Joins Chemokine Therapeutics Corp. (CTI.TO)' Clinical Advisory Board


8/12/2008 8:38:04 AM

VANCOUVER, BRITISH COLUMBIA--(Marketwire - August 12, 2008) - Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that Dr. Andrew Zhu has joined the Company's Oncology Clinical Advisory Board. Comprised of leading oncologists, the Advisory Board plays an important role in guiding the CTCE-9908 clinical development program.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES